Home » FDA Slaps Catalyst’s NDA With Refusal to File Letter
FDA Slaps Catalyst’s NDA With Refusal to File Letter
The FDA has rebuffed Catalyst Pharmaceuticals, firing off a refusal to file letter for the rare disease drugmaker’s NDA for Firdapse.
According to Catalyst, the letter neither commented on the submitted clinical data, nor made a judgment on the safety or efficacy of the candidate, which is being developed to treat Lambert Eaton myasthenic syndrome and congenital myasthenic syndromes.
Upcoming Events
-
23May
-
30May
-
13Jun
-
20Jun
-
21Oct